Advanced machine learning for Innovative Drug Discovery (AIDD)

The AIDD will develop innovative AI methods by combining theoretical expertise of academic partners with access to large volumes of valuable proprietary data and outstanding medicinal and synthetic chemistry domain expertise of the industrial partners. The project brings together the scientific expertise and resources of three large european pharma companies and academic partners with deep domain knowledge of computational drug design. Until now, this has been very difficult because of Intellectual property (IP) restrictions and resulting conflicts of interest and restrictions on dissemination characteristic of industry funded collaborations. The AIDD for the first time overcomes these restrictions by making all methodological developments available as open source. This will allow the widest possible dissemination of the project results to different target audiences, including SMEs. Dissemination will be also via publications in high impact journals, presentations at major scientific meetings and conferences, newsletters, open schools, professional networks, blogs, online lectures and courses, as well as public engagemen t via Open Days, public lectures to high schools and universities. The AIDD will include an innovative education program in the use of AI for chemical and biological data analysis. The project leverages a new curriculum that is introduced as a part of MSc programs at academic partners. AIDD will extend this educational program to include not only medicinal chemistry but also multidisciplinary and intersectoral areas such as material informatics, computational toxicology, agrochemistry, synthetic chemistry, biomaterials and other areas.